ERBB2 and invasive ductal breast carcinoma: Further, Her2 + and triple-negative patients had a higher expression of FBLN2 compared to LumA and LumB at lesions of invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), and control regions (Supplementary Fig. 7).